| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/11/1997 | EP0777493A1 Calcitonin gene related peptide receptor |
| 06/11/1997 | EP0777487A1 Treatment of disease and conditions associated with macrophage infiltration in particular stroke and myocardial infarction |
| 06/11/1997 | EP0777482A1 Combined preparation for the therapy of immune diseases |
| 06/11/1997 | EP0777480A1 Optic nerve health |
| 06/11/1997 | EP0777478A1 Inhibitors of rotamase enzyme activity |
| 06/11/1997 | EP0777474A1 Methods for the treatment of inflammatory joint disease |
| 06/11/1997 | EP0777473A1 Compositions and methods for the control of smoking |
| 06/11/1997 | EP0777470A1 Use of paracellular absorption enhancers such as glucose for enhancing the absorption of histamine h2-antagonists |
| 06/11/1997 | EP0777469A1 Use of insulin sensitisers for treating renal diseases |
| 06/11/1997 | EP0656786A4 Health supplements containing phyto-oestrogens, analogues or metabolites thereof. |
| 06/11/1997 | EP0654991B1 Inhalation powder containing antistatic agent |
| 06/11/1997 | EP0394409B1 Macrophage-derived inflammatory mediator (mip-2) |
| 06/10/1997 | US5637686 Tata-binding protein associated factor, nucleic acids |
| 06/10/1997 | US5637615 Antiaging agent |
| 06/10/1997 | US5637604 Treatment and control of ocular development |
| 06/10/1997 | US5637324 Medical food composition for metabolic detoxification |
| 06/10/1997 | US5637314 Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis |
| 06/10/1997 | US5637293 Stability; discoloration inhibition; mixture of kojic acid, ultraviolet radiation absorber, fatty ester and(or) glyceride |
| 06/10/1997 | US5637288 Chimeric antibody for detection and therapy of infectious and inflammatory lesions |
| 06/10/1997 | CA2106216C Chewable antacid compositions |
| 06/10/1997 | CA2040460C Drug delivery with thermoreversible gels |
| 06/08/1997 | CA2192298A1 Neuroprotective agents |
| 06/05/1997 | WO1997020063A1 THEREAPEUTIC APPLICATIONS FOR THE ANTI-T-BAM (CD40-L) MONOCLONAL ANTIBODY 5c8 |
| 06/05/1997 | WO1997019952A1 The ob receptor and methods of diagnosing and treating weight |
| 06/05/1997 | WO1997019946A1 Pyridopyrimidines |
| 06/05/1997 | WO1997019699A1 Drug composition |
| 06/05/1997 | WO1997019685A1 The use of cholinesterase inhibitors in the treatment of xerostomia |
| 06/05/1997 | WO1997019683A1 Hydrolysis-optimized lipid emulsions and use thereof |
| 06/05/1997 | WO1997019679A2 Use of nadph oxidase inhibitors for the manufacture of a medicament for prevention of atherosclerosis |
| 06/05/1997 | WO1997019673A2 Reduction of hair growth |
| 06/05/1997 | WO1997019672A1 Reduction of hair growth |
| 06/05/1997 | WO1997019593A1 Antimicrobial composition and methods of use therefor |
| 06/05/1997 | WO1997009973A3 Peripherally active anti-hyperalgesic opiates |
| 06/05/1997 | DE19648566A1 Isotonic lipid emulsion for parenteral application for nourishment, |
| 06/05/1997 | CA2238569A1 The ob receptor and methods of diagnosing and treating weight |
| 06/05/1997 | CA2238484A1 Antimicrobial composition and methods of use therefor |
| 06/04/1997 | EP0776334A1 Stable analogs of bioactive peptides containing disulfide linkages |
| 06/04/1997 | EP0776208A1 2,3-dihydro-1-(2,2,2-trifluoroethyl)-2-oxo-5-phenyl-1h-1,4-benzodiazepines |
| 06/04/1997 | EP0776206A1 Pharmaceutical formulation containing amoxycillin and potassium clavulanate |
| 06/04/1997 | EP0776205A1 Pharmaceutical formulation |
| 06/04/1997 | EP0776203A1 N-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1h-1,4-benzodiazepines |
| 06/04/1997 | EP0776201A1 Composition and method for treating anxiety |
| 06/04/1997 | EP0776200A1 Composition and method for protection against drug dependency |
| 06/04/1997 | CN1151168A Method and compositions for the dry powder formulation of interferons |
| 06/04/1997 | CN1151120A Method and compositions useful for inhibition of angiogenesis |
| 06/04/1997 | CN1151116A Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies |
| 06/03/1997 | US5635533 Antitumor agents |
| 06/03/1997 | US5635532 Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia |
| 06/03/1997 | US5635523 Retroviral protease inhibiting compounds |
| 06/03/1997 | US5635512 Method for modifying or resetting the prolactin rhythm of an insulin insensitive or diabetic animal or human |
| 06/03/1997 | US5635490 Administering polyether antibiotic and benzimidazole derivative |
| 06/03/1997 | US5635204 Method for transdermal induction of anesthesia, analgesia or sedation |
| 06/03/1997 | US5635184 Containing tree extract mixture of a-phellandrene, b-phellandrene, carvacrol, a-pinene, and b-pinene; topical |
| 06/03/1997 | CA2134038C Potentiation of drug response |
| 05/29/1997 | WO1997019194A1 METHODS FOR DETERMINING COMPOUNDS CAPABLE OF INHIBITING THE ACTIVITIES OF THE Ha-ras ONCOGENE |
| 05/29/1997 | WO1997019171A1 Epithelial membrane protein-1 |
| 05/29/1997 | WO1997019170A1 Receptor and nucleic acid molecule encoding said receptor |
| 05/29/1997 | WO1997018832A1 Interferon-polymer conjugates and process for preparing the same |
| 05/29/1997 | WO1997018822A1 Vertebrate deltex proteins, nucleic acids, and antibodies, and related methods and compositions |
| 05/29/1997 | WO1997018805A1 Combinational therapeutic methods employing nitric oxide scavengers |
| 05/29/1997 | WO1997018799A1 Use of a tnf alpha antagonist for treating neurogenic skin redness |
| 05/29/1997 | WO1997018782A1 Treatment with calcium channel blockers for drug-induced hypersensitivity |
| 05/29/1997 | WO1997013505A3 USE OF A η-RAR-SPECIFIC AGONIST LIGAND TO INCREASE APOPTOSIS RATE |
| 05/29/1997 | WO1997009343A3 Antagonists of the oncogenic activity of the protein mdm2, and use thereof in the treatment of cancers |
| 05/29/1997 | CA2238404A1 Vertebrate deltex proteins, nucleic acids, and antibodies, and related methods and compositions |
| 05/29/1997 | CA2238290A1 Methods for determining compounds capable of inhibiting the activities of the ha-ras oncogene |
| 05/29/1997 | CA2238028A1 Combinational therapeutic methods employing nitric oxide scavengers |
| 05/29/1997 | CA2236162A1 Epithelial membrane protein-1 |
| 05/28/1997 | EP0775486A1 Antibacterial, antimycotic and antviral compositions based on alpha-hydroxyalkanoic acids and squalene |
| 05/28/1997 | EP0775206A1 Dual hybrid system |
| 05/28/1997 | EP0775197A1 Enhanced activation of natural killer cells using an nk cell activator and a hydrogen peroxide scavenger or inhibitor |
| 05/28/1997 | EP0775130A1 Method for the preparation of (+/-)-calanolide a and intermediates thereof |
| 05/28/1997 | EP0774964A1 Controlled local delivery of chemotherapeutic agents for treating solid tumors |
| 05/28/1997 | CN1150804A Fibroblast growth factor-10 |
| 05/28/1997 | CA2163828A1 Process for screening factors on a paralysis model and process for preparing said model |
| 05/27/1997 | US5633351 Targeting protein-diagnostic/therapeutic agent conjugates having Schiff base linkages |
| 05/27/1997 | US5633285 Cytoprotective wound healing compositions and methods for preparing and using same |
| 05/27/1997 | US5633251 N-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1h-1,4-benzodiazepines |
| 05/27/1997 | US5633244 Histamine-h2 antagonists |
| 05/27/1997 | US5633238 Method for the treatment of schizophrenia |
| 05/27/1997 | US5633016 Administering cisplatin and topotecan synergistic mixture as antitumor agents |
| 05/27/1997 | US5632994 Fas associated proteins |
| 05/27/1997 | US5632981 Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
| 05/22/1997 | WO1997018309A1 E6 binding proteins |
| 05/22/1997 | WO1997018304A1 Methods for modulation of cholesterol transport |
| 05/22/1997 | WO1997018237A1 Chemokine from niddm pancreas |
| 05/22/1997 | WO1997018236A1 MIMOTOPES AND ANTI-MIMOTOPES OF HUMAN PLATELET GLYCOPROTEIN Ib/IX |
| 05/22/1997 | WO1997018223A1 Improved method and agents for inhibiting protein aging |
| 05/22/1997 | WO1997017993A1 Tumor associated internalizing antigens and methods for targeting therapeutic agents |
| 05/22/1997 | WO1997017990A1 Bactericidal permeability increasing protein (bpi) for treating conditions associated with corneal injury |
| 05/22/1997 | WO1997017989A1 Bactericidal/permeability increasing protein (bpi) for treating conditions associated with corneal transplantation |
| 05/22/1997 | WO1997017980A1 Treatment of cardiomyopathy by removal of autoantibodies |
| 05/22/1997 | WO1997017978A1 Administration media for analgesic, anti-inflammatory and anti-pyretic drugs containing nitrous oxide and pharmaceutical compositions containing such media and drugs |
| 05/22/1997 | WO1997017971A1 Use of epinastine in the treatment of pain |
| 05/22/1997 | WO1997017953A1 Method for the treatment, prevention or minimization of hair loss using a source of fatty acids |
| 05/22/1997 | WO1997007135A3 Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof |
| 05/22/1997 | WO1997005252A3 Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases |
| 05/22/1997 | WO1997005241A3 Methods and compositions for identifying morphogen analogs |
| 05/22/1997 | CA2240192A1 Methods for screening compounds that modulate cholesterol transport |
| 05/22/1997 | CA2237998A1 Chemokine from niddm pancreas |